Vera Therapeutics’ (VERA) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of Vera Therapeutics (NASDAQ:VERA) in a research note issued to investors on Friday morning,Weiss Ratings reports.

VERA has been the subject of a number of other research reports. JPMorgan Chase & Co. decreased their price target on shares of Vera Therapeutics from $56.00 to $53.00 and set an “overweight” rating for the company in a research note on Thursday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a research note on Thursday, September 18th. Bank of America started coverage on shares of Vera Therapeutics in a research note on Thursday, October 16th. They set a “buy” rating and a $48.00 price target for the company. Finally, Wolfe Research reiterated a “peer perform” rating on shares of Vera Therapeutics in a research note on Monday, August 4th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $61.50.

Vera Therapeutics Trading Up 3.6%

NASDAQ VERA opened at $29.22 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 17.03 and a quick ratio of 17.03. The firm’s fifty day moving average price is $26.32 and its 200 day moving average price is $23.74. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of -8.16 and a beta of 1.23. Vera Therapeutics has a 12 month low of $18.53 and a 12 month high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.38). During the same period in the previous year, the business posted ($0.62) EPS. On average, sell-side analysts expect that Vera Therapeutics will post -2.89 earnings per share for the current fiscal year.

Institutional Trading of Vera Therapeutics

Several hedge funds have recently made changes to their positions in VERA. Quantbot Technologies LP acquired a new stake in shares of Vera Therapeutics in the 2nd quarter worth $51,000. Quarry LP increased its holdings in shares of Vera Therapeutics by 25.0% in the 1st quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $60,000 after purchasing an additional 500 shares in the last quarter. AlphaQuest LLC increased its holdings in shares of Vera Therapeutics by 404.7% in the 1st quarter. AlphaQuest LLC now owns 4,007 shares of the company’s stock valued at $96,000 after purchasing an additional 3,213 shares in the last quarter. Virtus Investment Advisers LLC increased its holdings in shares of Vera Therapeutics by 14.8% in the 2nd quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock valued at $98,000 after purchasing an additional 539 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Vera Therapeutics by 192.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after purchasing an additional 2,757 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.